EMR · Sentiment — Financebot

Date: 2026-03-21 Analyst: Sentiment & Intelligence Current Price: ~$128.15 | 52-Week High: $165.15 | 52-Week Low: $90.06 Market Cap: $72.1B | Sector: Industrials — Specialty Industrial Machinery

1. Analyst Consensus

Current Rating Distribution (28 Analysts)

Period	Strong Buy	Buy	Hold	Sell	Strong Sell
Current	3	14	9	1	1
1 month ago	3	15	9	1	1
2 months ago	3	16	8	1	1
3 months ago	3	17	7	1	1

Consensus: Buy (17 Buy/Strong Buy vs 2 Sell/Strong Sell), but the trend is deteriorating — Buy ratings have declined from 20 to 17 over the past 3 months while Hold ratings have crept from 7 to 9.

Price Targets

Metric	Value	Upside from ~$128
Low	$104 - $126	-19% to -2%
Median	$167 - $171	+30% to +33%
High	$200 - $205	+56% to +60%

Recent Upgrades / Downgrades

Date	Firm	Action	Target
Feb 5, 2026	Deutsche Bank	Downgrade: Buy → Hold	$170
Jan 27, 2026	Oppenheimer	Downgrade: Outperform → Perform	—
Feb 4, 2026	Wells Fargo	Maintain Equal-Weight	$145 → $160
Feb 4, 2026	Citigroup	Maintain Buy	$165 → $174
Jan 5, 2026	UBS	PT Raise	$168

Signal: Two high-profile downgrades in quick succession (Oppenheimer, Deutsche Bank) right around earnings. The stock touched $164.50 in early February, then the downgrades and subsequent macro fears drove the selloff. The downgrades were valuation-driven — both firms still see a decent business but didn't think the stock deserved the premium it traded at near highs.

2. Q1 FY2026 Earnings (Reported Feb 3, 2026)

Headline Numbers

Metric	Actual	Consensus	Result
Revenue	$4.35B	~$4.33B	Beat (slight)
Adjusted EPS	$1.46	$1.41	Beat by 3.5%
Adj. Segment EBITDA Margin	27.7%	—	Exceeded expectations

Note: Revenue was down 10.5% sequentially (from $4.86B in Q4 FY2025), which spooked some investors, though seasonality explains much of this.

Guidance Update

Metric	Prior	Revised	Change
FY2026 Adj. EPS	$6.35 - $6.55	$6.40 - $6.55	Bottom raised $0.05
FY2026 Net Sales Growth	~5.5%	~5.5%	Maintained
Underlying Sales Growth	~4%	~4%	Maintained
Adj. Segment EBITA Margin	~28%	~28%	Maintained
Free Cash Flow	$3.5 - $3.6B	$3.5 - $3.6B	Maintained

Key Earnings Call Commentary

Orders strength: Underlying orders grew 9% YoY in Q1. North America orders up 18%, India up 22%, Middle East/Africa strong. Management cautioned 18% NA growth won't persist, but expects sustained high-single-digit growth.

Software traction: Annual contract value (ACV) for software grew 9% YoY to $1.6B. This is the thesis — the transformation from hardware conglomerate to automation + software platform is showing up in the numbers.

Test & Measurement (NI): Up 11% YoY, driven by secular demand for power infrastructure. NI integration delivered on the $200M run-rate cost synergy commitment.

Regional weakness: China outlook "turned a little more bearish" — management expects low single-digit negative growth in 2026. Western Europe remains soft. These are the headwind markets.

Tariff commentary: Management had built ~$130M of tariff impact into the plan. Seeing some relief vs. assumptions (positive developments in China/India), but new Mexico tariffs present a headwind. Net effect: roughly neutral so far.

Management tone: Confident but measured. Lal Karsanbhai emphasized the software + automation portfolio transformation, long-cycle order visibility, and margin expansion. Not cheerleading, not defensive — appropriately cautious on China/Europe while highlighting NA/India strength.

3. Corporate Transformation — Status Update

AspenTech (Fully Acquired March 2025)

Emerson completed the acquisition of remaining AspenTech shares in March 2025, eliminating the non-controlling interest overhang
AspenTech is now a fully-owned subsidiary, simplifying financials and removing the dual-stock complexity
Software ACV of $1.6B reflects the combined Emerson + AspenTech platform
Signal: Positive. The market had long disliked the complex AspenTech ownership structure. Full ownership is cleaner.

NI / Test & Measurement (Acquired Oct 2023)

Integration is effectively complete — $200M run-rate cost synergies achieved
T&M segment up 11% YoY, benefiting from power infrastructure buildout (AI data centers, grid modernization)
Signal: Integration success. This was a concern when acquired — so far it's delivering.

Copeland Divestiture (Completed Aug 2024)

Sold remaining 40% stake in Copeland JV for $1.5B in August 2024
Emerson is now a pure-play industrial automation and software company — no more HVAC/climate legacy
Cash from Copeland helped fund transformation and debt reduction
Signal: Positive. Clean portfolio, clear identity, higher-quality earnings mix.

Transformation Score Card

Emerson has executed one of the more impressive industrial transformations in recent years: - Divested: Copeland (climate), InSinkErator, Therm-O-Disc, other non-core assets - Acquired: AspenTech (industrial software), NI (test & measurement) - Result: ~$17.5B revenue automation + software pure-play with improving margins

4. Insider Activity

CEO Lal Karsanbhai — Recent Transactions

Date	Action	Shares	Price	Value
Mar 10, 2026	Sell	5,700	$142.32	$811K
Dec 3, 2025	Sell	7,263	$133.00	$966K
Dec 2025	Options Exercise	15,000	$45.50 (exercise)	$1.37M (value)

Remaining Direct Ownership: 281,393 shares (~$36M at current price)

5-Year Pattern: 1 buy, 4 sells over 5 years. The recent activity is routine options exercise + partial liquidation — not aggressive dumping. The March sell at $142.32 was near recent highs before the selloff to $128.

Assessment: The insider activity is not alarming but not encouraging either. No insider buying on the recent dip. The sells are modest relative to his total holdings (~2% of position each). This looks like scheduled compensation management, not a vote of no-confidence.

Notable: Karsanbhai was elected to Merck's board — a credibility signal, not a distraction concern given Emerson's transformation is largely complete.

5. Institutional Positioning

Category	Ownership
Institutional	76.5%
Insider	1.8%
Retail	21.7%

Top Holders

Holder	Shares	Ownership
Vanguard Group	53.4M	9.50%
BlackRock	~38M	~6.80%
State Street Global	~26M	~4.70%
JPMorgan Chase	Significant	Top 10
Bank of America	Significant	Top 10
Wellington Management	Significant	Top 10
Norges Bank (Norway Sovereign Fund)	Significant	Top 10

Assessment: Standard blue-chip institutional ownership. No single holder dominates (top 25 hold less than half). No activist investors surfaced in recent news. The presence of Norges Bank (sovereign wealth) signals quality perception.

6. Why Is EMR 22% Off Its 52-Week High?

The stock peaked at $165.15 in early February 2026 and has since fallen to ~$128. The decline unfolded in two waves:

Wave 1: Post-Earnings Downgrades (Feb 5-10, -11%)

EMR surged to $164.50 on Q1 earnings beat (Feb 3)
Deutsche Bank downgraded Buy → Hold (Feb 5) citing full valuation
Oppenheimer downgraded Outperform → Perform (Jan 27, just before)
Despite the earnings beat, the downgrades signaled the "good news is priced in" thesis
Stock fell from $164 to ~$148 in one week

Wave 2: Macro & Tariff Fear Cascade (Feb-March, -14%)

Broader industrial sector selloff on tariff escalation fears (Mexico tariffs specifically)
China outlook worsened — management itself turned "a little more bearish"
Western Europe industrial demand remained soft
Broader market rotation out of industrials into defensive sectors
EMR fell from $148 to $128

Is the Fear Justified?

Partially. The legitimate concerns: - China + Europe weakness is real and affects ~30-35% of revenue - Tariff uncertainty creates margin risk, even if currently built into guidance - Forward P/E of ~18x on $6.40-6.55 EPS isn't screaming value for a mid-single-digit grower

But the market is overweighting the negatives: - North America (50%+ of revenue) is genuinely strong — 18% order growth - India and Middle East are emerging growth engines - Software ACV growing 9% is a structurally higher-quality revenue stream - NI integration delivered, removing execution risk - $3.5-3.6B FCF guidance maintained — the cash generation machine is intact - The company just completed a multi-year transformation and is cleaner than it's been in decades

My read: The stock ran too far too fast to $165 on post-earnings euphoria, got slapped by well-timed downgrades, then got caught in the broader industrial/tariff fear trade. At $128, the market is pricing in a more pessimistic scenario than the fundamentals warrant. The ~22% decline is roughly half "justified correction from overvaluation" and half "macro fear premium."

7. Dividend King Status

Consecutive years of dividend increases: 69 years — one of the longest streaks in the market.

Metric	Value
Annual Dividend	$2.24/share ($0.56 quarterly)
Yield at $128	~1.75%
Payout Ratio	52.4% (trailing)
Conservative Est. Payout (FY2026)	~34% of adj. earnings
FCF Coverage	Comfortably covered by $3.5-3.6B FCF

Risk to the Streak: Very Low. The 34% payout ratio on adjusted earnings provides a massive margin of safety. Even in a recession scenario where earnings dropped 40%, the dividend would still be coverable. Emerson has maintained this streak through the GFC, COVID, and a complete corporate transformation — the streak is practically sacred to management.

The yield at 1.75% isn't a draw for income investors, but the growth + reliability combination is textbook Dividend King quality.

Sentiment Summary

Category	Signal	Direction
Analyst Consensus	Buy, but deteriorating	Cautiously Positive
Earnings Quality	Beat + raised EPS guide	Positive
Orders / Demand	9% underlying growth, strong NA	Positive
Regional Risk	China bearish, Europe weak	Negative
Tariff Exposure	~$130M built in, net neutral so far	Neutral / Watch
Transformation	Complete. Clean portfolio.	Strongly Positive
Insider Activity	Net selling, no buying on dip	Slightly Negative
Institutional Positioning	76% institutional, no activist pressure	Neutral / Stable
Dividend Safety	69-year streak, 34% payout ratio	Strongly Positive
Valuation vs. Price	22% off highs, ~18x forward P/E	Modestly Attractive

Thesis-Changing Flags

China deterioration could worsen. If China goes from "low single-digit negative" to something worse, it directly hits the automation segment. Monitor Q2 commentary closely.
Tariff escalation is the wildcard. $130M is built in, but a significant escalation (especially Mexico, where Emerson has manufacturing) could compress margins beyond the buffer.
The software ACV trajectory ($1.6B, +9%) is the key long-term signal. If this accelerates, EMR re-rates as a software-industrial hybrid. If it stalls, the premium valuation thesis weakens.
No insider buying on the dip. Not a red flag on its own, but if management believed the stock was deeply undervalued, you'd expect at least token purchases.